Yellow Fever Human Infection Model With YF-17D

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-02-17

Study Completion Date

2024-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

No antiviral treatment exists for yellow fever, only supportive care, and therefore we rely on prevention through vaccination. Although this vaccine is very effective, stockpiles are insufficient in outbreak situations and some people have a contraindication to be vaccinated. For those who are unprotected and at risk of yellow fever infection, treatment could be life saving.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Tolerability of an Antibody Against Yellow Fever Virus (TY014) in Humans

NCT03776786

Treatment of Acute Yellow Fever Virus Infection

COMPLETED PHASE1

Evaluation of the Safety and Immunogenicity of a Live Attenuated Human Metapneumovirus Vaccine

NCT01255410

Metapneumovirus

COMPLETED PHASE1

Safety, Tolerability & Immunogenicity of the Recombinant Plague Vaccine rF1V

NCT00097396

Pneumonic Plague Preventive Therapy

COMPLETED PHASE1

The Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Yellow Fever Vaccination

NCT04269265

Yellow Fever

COMPLETED PHASE1/PHASE2

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults

NCT03342898

Dengue

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

No antiviral treatment exists for yellow fever, only supportive care, and therefore we rely on prevention through vaccination. Although this vaccine is very effective, stockpiles are insufficient in outbreak situations and some people have a contraindication to be vaccinated. For those who are unprotected and at risk of yellow fever infection, treatment could be life saving.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Yellow Fever

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

human infection model of yellow fever with the yellow fever 17D vaccine and viruria (virus in urine) as readout

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

intervention arm

yellow fever vaccine arm (all participants receive the standard yellow fever vaccine (Stamaril)

Group Type OTHER

Yellow Fever Vaccine

Intervention Type DRUG

vaccination according to manufacturers manual (0.5mL subcutaneously in the arm)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Yellow Fever Vaccine

vaccination according to manufacturers manual (0.5mL subcutaneously in the arm)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Stamaril (yellow fever vaccine)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age 18-50 years

Exclusion Criteria

* contraindication to receive YF-17D (immune deficiency, thymus illness)
* previous YF vaccination
* pregnancy
* chicken egg allergy
* hypersensitivity to any other substance in the YF-17D vaccine
* interval of \< 4 weeks of another live attenuated vaccine

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes